Complications of CVCs in 382 consecutive patients receiving a stem cell transplantation (SCT) were analysed. Early complications were pneumothorax (3.6%), haematothorax (0.5%), dislocation (3%) and dysfunction (3.6%). Eighty-seven-associated infections (22%) were observed, leading to removal of the CVC in 26 patients. More bacteraemias were associated with double-or triple-lumen CVCs, 19% vs 5% in single lumen CVCs (P Ͻ 0.0001). Coagulase-negative staphylococci were the predominant microorganisms in 72%. A special point of investigation was CVC-associated thrombosis and the prophylactic value of nadroparin. Two consecutive regimens with nadroparin were used and compared; 7 days 2850 IE nadroparin and 10 days 5700 IE nadroparin. The incidence of CVC-associated thrombosis was 6.9% in 382 patients with 390 catheters. The incidence was 8% in patients receiving one of the prophylactic nadroparin regimens compared to 6% in a comparable control group without prophylaxis. A short course of nadroparin was unable to prevent thrombotic complications after discontinuation. Bone Marrow Transplantation (2000) 26, 1103-1106.
molecular weight heparin (LMWH) can prevent thrombosis in BMT patients with a CVC. [12] [13] [14] This retrospective study was undertaken to analyse the complications of indwelling CVCs with respect to thrombosis, infection and functioning in two groups of BMT recipients receiving two different doses of nadroparin (a LMWH). A previous group of comparable patients who did not receive nadroparin prophylaxis was used as a control group.
Patients and methods
Between January 1993 and December 1998, 382 consecutive patients who underwent allogeneic or autologous SCT in the haematology ward of the University Hospital Utrecht, were studied retrospectively with regard to CVC-associated complications. The patients were subdivided into three consecutive cohorts. The first cohort of 161 patients (163 catheters) received no prophylaxis. The second cohort consisted of 123 patients (125 catheters) who received prophylaxis with 2850 IE/day of nadroparin s.c. before insertion of the CVC and for a period of 6 days after insertion. The third cohort consisted of 98 patients (102 catheters) who also received prophylaxis with 5700 IE/day of nadroparin s.c. before insertion of the CVC and for a period of 10 days after insertion instead of 6 days. SCTs were performed for different indications and in the three groups the number of allogeneic and autologous SCTs were comparable (Table  1) .
Patients received a single-lumen catheter (tunnelled or non-tunnelled), double-, or triple-lumen tunnelled Hickman catheter (Bard Benelux NV, Nieuwegein, The Netherlands), which was inserted under sterile conditions in the operating room by a rotating group of residents supervised by one of three experienced surgeons. Haematological parameters, particularly coagulation characteristics, were assessed in each patient prior to surgery, and corrected whenever necessary. The vast majority of procedures were performed under local anaesthesia. As a routine, the infraclavicular approach was used to place the catheter into the subclavian vein. A standard introductory technique was used, consisting of direct puncture of the vein, introduction of a guide wire, radiological confirmation of correct wire position, dilatation of the introductory route, creation of a subcutaneous tunnel, and introduction of the catheter with the tip positioned in the superior vena cava a few centimetres from the right atrium. Each lumen was tested for adequate aspiration and infusion characteristics, and flushed with heparin-saline (100 IU/ml). A postoperative chest X-ray was performed routinely to detect pneumothorax and to confirm correct catheter placement. All patients received 2 g of cephalotin intravenously 1 h before insertion of the CVC. Catheters were flushed once a day with 9 ml of 0.9% saline solution followed by 7 ml of heparin (100 EH/ml) and after every blood withdrawal, administration of medicines and blood products. Some patients had more than one catheter sited because of a previous complication (Table 2) .
Conditioning therapy consisted of cyclophosphamide and total body irradiation. Before conditioning all patients commenced antimicrobial prophylaxis with ciprofloxacin 500 mg twice daily and antifungal prophylaxis with oral amphotericin B 200 mg four times daily plus fluconazole 50 mg once daily. This regimen was continued until the granulocyte count was Ͼ500 × 10 6 /l. Patients were treated after SCT with cephalotin 1 g six times daily intravenously for 10 days for prevention of ␣-haemolytic streptococcal bacteraemias.
We analysed all acute complications due to insertion of the CVC, dysfunctioning of the CVC, CVC-associated infections and thrombosis. Bacteraemia was defined as a Table 2 Complications after placement of a CVC 
a Disutility, leakage and temporary obstruction.
positive blood culture (aerobic and/or anaerobic) in two blood samples (one withdrawn from the CVC and one from a peripheral vein). Exit site infection was defined as erythema, tenderness, induration and/or purulence within 2 cm of the skin exit site of the CVC. Tunnel infection was defined as development of erythema and/or tenderness along the subcutaneous tract of the CVC at a distance Ͼ2 cm from the exit site. 15 We were particularly interested in the incidence of thrombosis in the three different groups in relation to type of prophylaxis. We therefore looked at the occurrence of thrombosis per cohort and per catheter type (single, double or triple lumen). In patients who developed clinical signs of thrombosis, ie swelling and/or redness of the limb or venous engorgement, thrombosis was confirmed with a Doppler ultrasound. Patients with a documented thrombus were treated with heparin intravenously for 5 days after removal of the CVC, followed by anti-coagulant therapy for a period of 3 months, if possible.
Statistical analysis of the difference in incidence of bacteraemias in the single lumen compared to the double-and triple-lumen group was performed using the chi-square test. A Fisher's exact test was used to analyse the occurrence of thrombosis in the different groups.
Results
Three hundred and ninety catheters were placed in 382 consecutive patients from January 1993 to December 1998. These patients comprised the entire study group. A total of 194 single-lumen catheters, 154 Hickman double-lumen catheters and 42 Hickman triple-lumen catheters were placed.
Complications
The acute complications encountered during or just after insertion for all three cohorts combined were 14 pneumothorax (3.6%), drainage was needed in six and haematothorax occurred in two (0.5%). Other problems were dislocation 12 (3%), dysfunctioning eight (2%) and leakage six (1.6%). Table 2 details these complications per catheter type. No significant differences were observed between the different types of CVC.
CVC-associated infections
A total of 87 infections (22%) in 382 patients was observed, leading to removal of the CVC in 26 patients. There were 15 (8%) exit site infections, four (2%) tunnel infections and nine (5%) bacteraemias in 186 patients with 194 single lumen catheters. In 154 patients with a double lumen catheter there were 11 (7%) exit site infections, five (3%) tunnel infections and 31 (20%) bacteraemias, and in 42 patients with a triple lumen catheter there were five (12%) exit site infections, one (2%) tunnel infection and six (15%) bacteraemias, respectively. Causative microorganisms of the 46 catheter-associated bacteremias were coagulase-negative staphylococci (33), corynebacterium species (five), E. coli (four), ␣-haemolytic streptococci (four) and enterococci (two). In two cases, more than one causative micro- 9 (5) 31 (20) 6 (15) organism was found. Table 3 shows the type of infection per catheter. There was a significant difference between the number of bacteraemias in the single-lumen group compared to the double-or triple-lumen group (9/194 vs 37/196, respectively P Ͻ 0.0001).
CVC-associated thrombosis
Twenty-seven of 382 (7%) patients developed clinical signs of a catheter-associated thrombosis. In the first group not receiving nadroparin prophylaxis, 10 patients (6%) developed thrombosis, in the second group receiving 7 days 2850 IE/day nadroparin, 10 patients (8%) and in the third group receiving 10 days 5700 IE/day nadroparin, seven patients (7%), respectively. Rate of thrombosis per group and per catheter type is shown in Table 4 . No significant differences between the three groups were observed (P = 0.58). Thrombosis was confirmed by Doppler ultrasound; extension to adjacent veins occurred but no thrombosis in the superior vena cava was observed. Thrombosis occurred at a median of 22 days (range 5-92 days) after placement of the CVC. Only one patient developed thrombosis after 92 days. All other patients developed thrombosis within 40 days after placement of the CVC.
Discussion
This study describes the complications associated with CVCs during a period of 5 years in our transplantation unit.
Complications such as pneumothorax (3.6%), haematothorax (0.5%), dislocation (3%) or dysfunction (3.6%) were observed. These data are comparable to other studies. [16] [17] [18] The same is true for the occurrence of CVC-associated infections, eg 21%. 19 CVC-associated bacteraemias were observed significantly more often in the patients with double-or triple-lumen catheters (18.9%) compared to single- Table 4 CVC-associated thrombosis Bone Marrow Transplantation lumen catheters (4.6%) (P Ͻ 0.0001 chi-square). This could be explained by the fact that patients receiving a doubleor triple-lumen CVC are patients who receive an allogeneic SCT or a matched unrelated donor (MUD)-SCT. They are neutropenic for a longer period of time, receive more medication and parenteral nutrition and develop more complications before bone marrow recovery. Neutropenia is a well known risk factor for the development of catheter-associated infections. 20, 21 The only difference between the three groups was no nadroparin, 7 days 2850 IE nadroparin or 10 days 5700 IE nadroparin.
CVC-associated thrombosis is another serious complication in patients receiving an SCT. Thrombosis causes significant morbidity in addition to the small risk of pulmonary embolism. The CVC needs to be removed at a critical time when the patient is still aplastic, needs parenteral hyperalimentation, intravenous medication, blood products, frequent blood sampling and so on. Therefore, nadroparin prophylaxis has been given in our hospital since September 1995 at two different doses for prevention of CVC-related thrombosis. The groups were comparable with respect to underlying disease and type of SCT. The risk factors believed to contribute to catheter-induced thrombosis, such as chemotherapy, use of parenteral nutrition, type of transplant were comparable between all three cohorts.
The most striking finding from our analysis was that prophylaxis with nadroparin appeared not to decrease the rate of CVC-associated thrombosis. The occurrence of thrombosis was 17 out of 221 (8%) in patients taking prophylaxis compared to 10 out of 161 (6%) patients receiving no prophylaxis. The rate of thrombosis in our patient population is in concordance with other studies. 4, 5 Hickman double-or triple-lumen CVCs were most frequently associated with thrombosis, 9.6% vs 3.7% in single lumen CVCs. However, in the double-or triple-lumen group no effect of nadroparin could be observed either, with 10% thrombosis occurring in patients receiving prophylaxis and 9% in patients taking no prophylaxis. In our study, increasing the dose of LMWH from 2850 IE to 5700 IE and administering it for 10 days rather than 7 did not result in a better outcome. A possible explanation for our negative results could be the short time course of nadroparin administration. Continuation of nadroparin prophylaxis for a longer period might be more effective but could also increase the risk of haemorrhages in these high risk patients. Controlled trials may resolve these issues. There are multiple different LMWHs available which differ in molecular weight, antifactor Xa activity and degree of protein binding, so generalised conclusions from this study of nadroparin are not possible. Only properly sized comparative data can allow conclusions to be drawn about the relative efficacy of the different LMWHs. 22 New approaches to preventing CVC-associated thrombosis are mandatory. Our data suggest that thrombosis was initiated at the insertion site of the CVC. It may be that other insertion techniques with less vessel wall trauma will reduce the risk of CVC-associated thrombosis. Another possibility could be the use of minidose warfarin that could be administered for a longer time without risk of haemorrhage.
14 Controlled trials, however, are lacking with this regimen. Thrombosis was observed at a median of 22 days after insertion of the CVC, so adequate anticoagulation during the first weeks after insertion might be more useful. The drawback of such an approach is that the CVC should be inserted earlier, before admission to hospital for SCT.
In conclusion, this study shows that the use of CVCs in patients undergoing a SCT is associated with 10% early complications, 22% infections and 6.9% thrombosis. We found no effect in this study of two regimens using prophylactic nadroparin on the incidence of CVC-associated thrombosis.
